Rhythm Pharmaceuticals Non Operating Income Net Other Over Time
| RYTM Stock | USD 96.35 3.43 3.44% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Rhythm Pharmaceuticals Performance and Rhythm Pharmaceuticals Correlation. Will Biotechnology sector continue expanding? Could Rhythm diversify its offerings? Factors like these will boost the valuation of Rhythm Pharmaceuticals. Anticipated expansion of Rhythm directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Rhythm Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (3.10) | Revenue Per Share | Quarterly Revenue Growth 0.543 | Return On Assets | Return On Equity |
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Rhythm Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Rhythm Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Rhythm Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Non Operating Income Net Other Analysis
Compare Rhythm Pharmaceuticals and related stocks such as Revolution Medicines, Akero Therapeutics, and Avidity Biosciences Non Operating Income Net Other Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RVMD | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 929 K | 929 K | 929 K | 929 K | 836.1 K | 1.3 M |
| PTGX | 208 K | 208 K | 208 K | 208 K | 208 K | 208 K | 208 K | 940 K | 2.5 M | 2.8 M | 269 K | 294 K | 4 M | 4 M | 4 M | 4.6 M | 4.8 M |
| STOK | 801 K | 801 K | 801 K | 801 K | 801 K | 801 K | 801 K | 801 K | 801 K | 801 K | 801 K | 140 K | 167 K | 167 K | 167 K | 150.3 K | 295.5 K |
| QURE | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 7.3 M | 7.3 M | 749 K | (12.2 M) | 29.7 M | 29.7 M | 29.7 M | 29.7 M | 34.1 M | 35.8 M |
| RCKT | (46.4 M) | (46.4 M) | (46.4 M) | (46.4 M) | (46.4 M) | (46.4 M) | 443 K | 819 K | 2.5 M | 4.6 M | 1.6 M | 156 K | 156 K | 156 K | 156 K | 179.4 K | 188.4 K |
| SLDB | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 116 K | 66 K | 20.5 M | 20.5 M | 20.5 M | 23.5 M | 24.7 M |
| MGTX | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | 3.6 M | 4.7 M | (6.1 M) | (8.7 M) | (8.7 M) | (8.7 M) | (7.8 M) | (7.4 M) |
| NUVL | (521 K) | (521 K) | (521 K) | (521 K) | (521 K) | (521 K) | (521 K) | (521 K) | (521 K) | (521 K) | (521 K) | (521 K) | 4.3 M | 4.3 M | 4.3 M | 4.9 M | 5.1 M |
| VTYX | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | 4.7 M | 4.7 M | 4.7 M | 5.4 M | 5.7 M |
| CGEM | 469 K | 469 K | 469 K | 469 K | 469 K | 469 K | 469 K | 469 K | 469 K | 469 K | 469 K | 469 K | 6.7 M | 6.7 M | 6.7 M | 7.7 M | 3.9 M |
| KNSA | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 6 M | 1.1 M | 97 K | 1.3 M | 1.3 M | 1.3 M | 1.1 M | 2.1 M |
| PLRX | 112 K | 112 K | 112 K | 112 K | 112 K | 112 K | 112 K | 112 K | 112 K | 112 K | 112 K | 272 K | 3.9 M | 3.9 M | 3.9 M | 4.5 M | 4.7 M |
| SNDX | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (269 K) | (27 K) | (79 K) | 622 K | 605 K | 605 K | 605 K | 605 K | 695.8 K | 730.5 K |
| VRDN | 165 K | 165 K | 165 K | 165 K | 165 K | 165 K | 165 K | 165 K | 165 K | 165 K | 165 K | 169 K | 4.7 M | 4.7 M | 4.7 M | 5.4 M | 5.7 M |
| RLAY | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 826 K | 8.8 M | 8.8 M | 8.8 M | 10.1 M | 10.6 M |
| BDTX | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 1.3 M | 1.7 M | 1.7 M | 1.7 M | 1.5 M | 1.4 M |
| ARVN | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 2.4 M | (18.7 M) | 5.6 M | 4.4 M | 1.6 M | 1.6 M | 1.6 M | 1.8 M | 1.9 M |
Rhythm Pharmaceuticals and related stocks such as Revolution Medicines, Akero Therapeutics, and Avidity Biosciences Non Operating Income Net Other description
My Equities
My Current Equities and Potential Positions
| Rhythm Pharmaceuticals | RYTM |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 222 Berkeley Street, |
| Exchange | NASDAQ Exchange |
USD 96.35
Check out Rhythm Pharmaceuticals Performance and Rhythm Pharmaceuticals Correlation. To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Rhythm Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.